{"mainPropery":{"diseaseId":231,"diseaseName":"Leukoencephalopathy with vanishing white matter","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/231/leukoencephalopathy-with-vanishing-white-matter","synonyms":["Childhood ataxia with diffuse central nervous system hypomyelination","CACH syndrome","CACH/VWM syndrome","Myelinosis centralis diffusa","Cree leukoencehalopathy","Childhood ataxia with central nervous system hypomyelination/vanishing white matter","CACH/VWM","Vanishing white matter leukodystrophy","Vanishing white matter disease"],"synonyms-with-source":[{"name":"Childhood ataxia with diffuse central nervous system hypomyelination"},{"name":"CACH syndrome"},{"name":"CACH/VWM syndrome"},{"name":"Myelinosis centralis diffusa"},{"name":"Cree leukoencehalopathy"},{"name":"Childhood ataxia with central nervous system hypomyelination/vanishing white matter","source":"GeneReviews"},{"name":"CACH/VWM","source":"GeneReviews"},{"name":"Vanishing white matter leukodystrophy","source":"GHR"},{"name":"Vanishing white matter disease","source":"GHR"}],"identifiers":[{"identifierType":"OMIM","identifierId":"603896"},{"identifierType":"ORPHANET","identifierId":"135"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases"}],"organizations":[{"resourceID":46,"resourceName":"euro-ATAXIA (European Federation of Hereditary Ataxias)","abbreviation":"","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"","url":"https://www.euroataxia.org/","freeText":""},{"resourceID":195,"resourceName":"United Leukodystrophy Foundation","abbreviation":"ULF","address1":"224 North Second Street","address2":"Suite 2","address3":"","address4":"","address5":"","city":"DeKalb","state":"IL","zip":"60115 ","country":"United States","phone":"+1-815-748-3211 ","tty":"","tollFree":"1-800-728-5483","fax":"+1-815-748-0844","email":"office@ulf.org","url":"https://ulf.org/","freeText":""},{"resourceID":2219,"resourceName":"Alex The Leukodystrophy Charity","abbreviation":"Alex TLC","address1":"45 Peckham High Street","address2":"","address3":"","address4":"","address5":"","city":"London","state":"","zip":"SE15 5EB","country":"United Kingdom","phone":" 020 7701 4388","tty":"","tollFree":"","fax":"","email":"info@alextlc.org","url":"https://www.alextlc.org","freeText":""},{"resourceID":3478,"resourceName":"European Association against Leukodystrophy","abbreviation":" ELA","address1":"2, rue Mi-les-Vignes","address2":"BP 61024 54521","address3":"Laxou Cedex","address4":"","address5":"","city":"","state":"","zip":"","country":"France","phone":"","tty":"","tollFree":"","fax":"","email":"http://ela-asso.com/en/contact-2/","url":"http://ela-asso.com/en/","freeText":""},{"resourceID":3930,"resourceName":"The VWM Families Foundation","abbreviation":"","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"vwmfoundation@gmail.com","url":"https://vwmff.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/603896' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=603896' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Leukoencephalopathy with vanishing white matter. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/leukoencephalopathy-with-vanishing-white-matter' target='_blank'>MedlinePlus Genetics</a> contains information on Leukoencephalopathy with vanishing white matter. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1858991' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"Orphanet is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n<a href='http://www.orpha.net/data/patho/Pro/en/CACHSyndrome-FRenPro3664.pdf' target='_blank'>Orphanet</a><br /><a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=135' target='_blank'>Orphanet</a><br />","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1258/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:603896' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":4284,"questionText":"What is leukoencephalopathy with vanishing white matter?","answerText":"<strong>Leukoencephalopathy with vanishing white matter</strong> is a progressive disorder that mainly affects the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002311.htm\" target=\"_blank\">central nervous system</a> (CNS). This disorder causes deterioration of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002344.htm\" target=\"_blank\">white matter</a>, which consists of nerve fibers covered by <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002261.htm\" target=\"_blank\">myelin</a> (the substance that protects the nerves). Most affected people begin to have signs and symptoms during childhood, but symptoms may first become apparent anywhere from before birth to adulthood. Symptoms may include difficulty coordinating movements (ataxia); muscle stiffness (spasticity); and&nbsp;<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001622.htm\" target=\"_blank\">optic atrophy</a>. Symptoms may worsen rapidly with episodes of fever, after head trauma, or with other stresses on the body. This disorder may be caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in any of 5 <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">genes</a> and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner. There is no specific treatment, and prognosis seems to correlate with the age of onset, the earliest forms being more severe.[3221][9638][9639]<br />","dateModified":"2015-09-14T00:00:00"},"basicQuestions":[{"questionId":9390,"questionText":"What causes leukoencephalopathy with vanishing white matter?","answerText":"Leukoencephalopathy with vanishing white matter is a genetic condition caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in any of 5 genes - <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B1\" target=\"_blank\">EIF2B1</a></em>, <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B2\" target=\"_blank\">EIF2B2</a></em>, <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B3\" target=\"_blank\">EIF2B3</a></em>, <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B4\" target=\"_blank\">EIF2B4</a></em>, and <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B5\" target=\"_blank\">EIF2B5</a></em>. These genes give the body instructions to make the five parts (subunits) of a <a href=\"http://ghr.nlm.nih.gov/handbook/howgeneswork/protein\" target=\"_blank\">protein</a> called eIF2B. This protein helps regulate overall production of protein in cells (protein synthesis). Proper regulation of protein synthesis ensures that the correct levels of protein are available for cells to cope with changing conditions and stress. <br />\r\n<br />\r\nMutations in any of these 5 genes results in partial loss of eIF2B function, making it more difficult for cells to regulate protein synthesis and deal with changing conditions and stress. Researchers believe that cells in the white matter may be particularly affected by an abnormal response to stress, thus causing the signs and symptoms of this condition.[3221]<br />\r\n<br />\r\nApproximately 90% of affected people have been found to have mutations in one of these 5 genes. Approximately 10% of families who have been diagnosed by MRI and clinical features do not have an identifiable mutation, suggesting that additional genes may also be responsible for the condition.[9638]","dateModified":"2015-09-14T10:40:00","resourceClassificationName":"Cause","references":[{"referenceId":3221,"authors":"","articleTitle":"Leukoencephalopathy with vanishing white matter","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/leukoencephalopathy-with-vanishing-white-matter","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9638,"authors":"Raphael Schiffmann, Anne Fogli, Marjo S van der Knaap, and Odile Boespflug-Tanguy","articleTitle":"Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter","bookWebsiteJournalTitle":"GeneReviews","date":"August 9, 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1258/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9391,"questionText":"How is leukoencephalopathy with vanishing white matter inherited?","answerText":"Leukoencephalopathy with vanishing white matter is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[9638] This means that a person must have a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in both copies of the responsible gene to be affected. The parents of an affected person usually each carry one mutated copy of the gene and are referred to as carriers. Carriers typically do not have signs or symptoms of the condition. When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) chance to have the condition, a 50% (1 in 2) risk to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.","dateModified":"2015-09-14T10:40:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9638,"authors":"Raphael Schiffmann, Anne Fogli, Marjo S van der Knaap, and Odile Boespflug-Tanguy","articleTitle":"Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter","bookWebsiteJournalTitle":"GeneReviews","date":"August 9, 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1258/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4285,"questionText":"How might leukoencephalopathy with vanishing white matter be treated?","answerText":"Treatment for leukoencephalopathy with vanishing white matter is supportive, aiming to alleviate symptoms. Management may include physical therapy and rehabilitation for motor dysfunction (mainly spasticity and ataxia); and anti-seizure medications for seizures.[9638]<br />\r\n<br />\r\nInfections and fevers should be prevented when possible through the use of vaccinations; low-dose maintenance antibiotics during winter months; antibiotics for minor infections; and antipyretics (fever-reducing medications) for fever. For children, wearing a helmet outside can help minimize the effects of head trauma. Contact sports, head trauma, and stressful situations (including high body temperature) should be avoided.[9638]<br />\r\n<br />\r\n<a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1258/#cach.Management\" target=\"_blank\">More detailed information about the management of&nbsp;leukoencephalopathy with vanishing white matter is available on the GeneReviews Web site</a>.","dateModified":"2015-09-14T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":9638,"authors":"Raphael Schiffmann, Anne Fogli, Marjo S van der Knaap, and Odile Boespflug-Tanguy","articleTitle":"Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter","bookWebsiteJournalTitle":"GeneReviews","date":"August 9, 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1258/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":12052,"relatedDiseaseName":"Demyelinating disease of central nervous system","relation":"Parent","isRare":false,"hasGardPage":false},{"relatedDiseaseId":6895,"relatedDiseaseName":"Leukodystrophy","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":53174,"abbreviatedInquiry":"When pregnant, can exposure to carbon disulfide be a factor in vanishing white matter for the child? Or is this purely due to genetics?","caseQuestions":[{"questionId":9390,"questionText":"What causes leukoencephalopathy with vanishing white matter?","answerText":"Leukoencephalopathy with vanishing white matter is a genetic condition caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in any of 5 genes - <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B1\" target=\"_blank\">EIF2B1</a></em>, <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B2\" target=\"_blank\">EIF2B2</a></em>, <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B3\" target=\"_blank\">EIF2B3</a></em>, <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B4\" target=\"_blank\">EIF2B4</a></em>, and <em><a href=\"http://ghr.nlm.nih.gov/gene/EIF2B5\" target=\"_blank\">EIF2B5</a></em>. These genes give the body instructions to make the five parts (subunits) of a <a href=\"http://ghr.nlm.nih.gov/handbook/howgeneswork/protein\" target=\"_blank\">protein</a> called eIF2B. This protein helps regulate overall production of protein in cells (protein synthesis). Proper regulation of protein synthesis ensures that the correct levels of protein are available for cells to cope with changing conditions and stress. <br />\r\n<br />\r\nMutations in any of these 5 genes results in partial loss of eIF2B function, making it more difficult for cells to regulate protein synthesis and deal with changing conditions and stress. Researchers believe that cells in the white matter may be particularly affected by an abnormal response to stress, thus causing the signs and symptoms of this condition.[3221]<br />\r\n<br />\r\nApproximately 90% of affected people have been found to have mutations in one of these 5 genes. Approximately 10% of families who have been diagnosed by MRI and clinical features do not have an identifiable mutation, suggesting that additional genes may also be responsible for the condition.[9638]","dateModified":"2015-09-14T10:40:00","resourceClassificationName":"Cause","references":[{"referenceId":3221,"authors":"","articleTitle":"Leukoencephalopathy with vanishing white matter","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/leukoencephalopathy-with-vanishing-white-matter","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9638,"authors":"Raphael Schiffmann, Anne Fogli, Marjo S van der Knaap, and Odile Boespflug-Tanguy","articleTitle":"Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter","bookWebsiteJournalTitle":"GeneReviews","date":"August 9, 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1258/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9391,"questionText":"How is leukoencephalopathy with vanishing white matter inherited?","answerText":"Leukoencephalopathy with vanishing white matter is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[9638] This means that a person must have a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in both copies of the responsible gene to be affected. The parents of an affected person usually each carry one mutated copy of the gene and are referred to as carriers. Carriers typically do not have signs or symptoms of the condition. When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) chance to have the condition, a 50% (1 in 2) risk to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.","dateModified":"2015-09-14T10:40:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9638,"authors":"Raphael Schiffmann, Anne Fogli, Marjo S van der Knaap, and Odile Boespflug-Tanguy","articleTitle":"Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter","bookWebsiteJournalTitle":"GeneReviews","date":"August 9, 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1258/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9392,"questionText":"Is there an association between maternal carbon disulfide exposure and leukoencephalopathy with vanishing white matter in a child?","answerText":"Leukoencephalopathy with vanishing white matter is a genetic condition caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in genes involved in the regulation of the production of <a href=\"http://ghr.nlm.nih.gov/handbook/howgeneswork/protein\" target=\"_blank\">protein</a>; it is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[3221] There are cases in which an affected person does not appear to have an identifiable mutation in one of the 5 genes known to be responsible for the condition (approximately 10% of affected people). However, these cases are thought to be due to additional, responsible genes that have not yet been identified.[9638]<br />\r\n<br />\r\nTo our knowledge, there is no evidence that suggests or states that there is any association between maternal carbon disulfide exposure and leukoencephalopathy with vanishing white matter in a child. Long-term exposure to carbon disulfide may contribute to the development of various other neurologic effects in an exposed person. Reproductive effects that have been observed in people exposed to carbon disulfide by inhalation include decreased sperm count and menstrual disturbances.[9646] In experimental animal studies, carbon disulfide has been shown to increase malformations, but at dose levels much higher than those anticipated in humans.[9636]","dateModified":"2015-09-16T00:00:00","references":[{"referenceId":3221,"authors":"","articleTitle":"Leukoencephalopathy with vanishing white matter","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/leukoencephalopathy-with-vanishing-white-matter","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9636,"authors":"","articleTitle":"Carbon Disulfide","bookWebsiteJournalTitle":"REPROTOX","date":"May 9, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":"REPROTOX"},{"referenceId":9638,"authors":"Raphael Schiffmann, Anne Fogli, Marjo S van der Knaap, and Odile Boespflug-Tanguy","articleTitle":"Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter","bookWebsiteJournalTitle":"GeneReviews","date":"August 9, 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1258/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9646,"authors":"","articleTitle":"Carbon disulfide","bookWebsiteJournalTitle":"Environmental Protection Agency","date":"January, 2000","volume":"","pages":"","url":"http://www.epa.gov/airtoxics/hlthef/carbondi.html","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":12793,"phenoTypeName":"Juvenile onset","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9851,"phenoTypeName":"Macrocephaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10089,"phenoTypeName":"Blindness","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":12136,"phenoTypeName":"Cerebral hypomyelination","percentRanges":"-"},{"phenoTypeId":9252,"phenoTypeName":"Cessation of head growth","percentRanges":"-"},{"phenoTypeId":13657,"phenoTypeName":"CNS demyelination","percentRanges":"-"},{"phenoTypeId":15573,"phenoTypeName":"Decreased circulating progesterone","percentRanges":"-"},{"phenoTypeId":13990,"phenoTypeName":"Delusions","percentRanges":"-"},{"phenoTypeId":5154,"phenoTypeName":"Developmental regression","percentRanges":"-"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","percentRanges":"-"},{"phenoTypeId":6009,"phenoTypeName":"Emotional lability","percentRanges":"-"},{"phenoTypeId":13043,"phenoTypeName":"Fever","percentRanges":"-"},{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","percentRanges":"-"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","percentRanges":"-"},{"phenoTypeId":13847,"phenoTypeName":"Gliosis","percentRanges":"-"},{"phenoTypeId":8721,"phenoTypeName":"Lethargy","percentRanges":"-"},{"phenoTypeId":11430,"phenoTypeName":"Leukoencephalopathy","percentRanges":"-"},{"phenoTypeId":11437,"phenoTypeName":"Memory impairment","percentRanges":"-"},{"phenoTypeId":8716,"phenoTypeName":"Muscular hypotonia","percentRanges":"-"},{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","percentRanges":"-"},{"phenoTypeId":14143,"phenoTypeName":"Personality changes","percentRanges":"-"},{"phenoTypeId":1383,"phenoTypeName":"Premature ovarian insufficiency","percentRanges":"-"},{"phenoTypeId":14013,"phenoTypeName":"Primary amenorrhea","percentRanges":"-"},{"phenoTypeId":1375,"phenoTypeName":"Primary gonadal insufficiency","percentRanges":"-"},{"phenoTypeId":6060,"phenoTypeName":"Secondary amenorrhea","percentRanges":"-"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","percentRanges":"-"},{"phenoTypeId":8711,"phenoTypeName":"Spasticity","percentRanges":"-"},{"phenoTypeId":11410,"phenoTypeName":"Unsteady gait","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Leukoencephalopathy_with_vanishing_white_matter"}